Physician profile
Daniel L Cochran
NPI 1770510372
$1,351.46
in general payments reported to CMS, 2019-2025
10 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.02 · 2020: $30.06 · 2023: $354 · 2024: $787 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $425.11 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $333.08 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $185.53 | 2024 | Tepezza, Otezla, Repatha |
| Lilly USA, LLC | $124.20 | 2023-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $76.37 | 2024 | |
| Pfizer INC. | $71.10 | 2020-2024 | |
| Abbott Laboratories | $65.19 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $32.91 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $23.95 | 2023 | Arexvy, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.